Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers

NCT04911660 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Kidney Stone

Interventions

DRUG: Empagliflozin 25 MG
OTHER: Placebo

Sponsor

Insel Gruppe AG, University Hospital Bern

Collaborators

[object Object]
[object Object]